全文获取类型
收费全文 | 136311篇 |
免费 | 9445篇 |
国内免费 | 659篇 |
专业分类
耳鼻咽喉 | 1652篇 |
儿科学 | 3443篇 |
妇产科学 | 2449篇 |
基础医学 | 17401篇 |
口腔科学 | 2906篇 |
临床医学 | 13332篇 |
内科学 | 28056篇 |
皮肤病学 | 1766篇 |
神经病学 | 11958篇 |
特种医学 | 5450篇 |
外科学 | 21860篇 |
综合类 | 1975篇 |
现状与发展 | 1篇 |
一般理论 | 173篇 |
预防医学 | 12409篇 |
眼科学 | 2918篇 |
药学 | 9630篇 |
2篇 | |
中国医学 | 179篇 |
肿瘤学 | 8855篇 |
出版年
2023年 | 672篇 |
2022年 | 1050篇 |
2021年 | 2575篇 |
2020年 | 1467篇 |
2019年 | 2397篇 |
2018年 | 2924篇 |
2017年 | 2112篇 |
2016年 | 2232篇 |
2015年 | 2720篇 |
2014年 | 4025篇 |
2013年 | 6064篇 |
2012年 | 8874篇 |
2011年 | 9445篇 |
2010年 | 5272篇 |
2009年 | 4824篇 |
2008年 | 8401篇 |
2007年 | 9006篇 |
2006年 | 8583篇 |
2005年 | 8725篇 |
2004年 | 8381篇 |
2003年 | 7872篇 |
2002年 | 7684篇 |
2001年 | 1282篇 |
2000年 | 1053篇 |
1999年 | 1402篇 |
1998年 | 1654篇 |
1997年 | 1338篇 |
1996年 | 1280篇 |
1995年 | 1233篇 |
1994年 | 1044篇 |
1993年 | 1022篇 |
1992年 | 843篇 |
1991年 | 863篇 |
1990年 | 757篇 |
1989年 | 742篇 |
1988年 | 758篇 |
1987年 | 744篇 |
1986年 | 762篇 |
1985年 | 848篇 |
1984年 | 910篇 |
1983年 | 871篇 |
1982年 | 1135篇 |
1981年 | 1162篇 |
1980年 | 965篇 |
1979年 | 631篇 |
1978年 | 672篇 |
1977年 | 599篇 |
1976年 | 519篇 |
1975年 | 471篇 |
1974年 | 471篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
71.
72.
Najat C Daw Wayne L Furman Clinton F Stewart Lisa C Iacono Mark Krailo Mark L Bernstein Janet E Dancey Rose Anne Speights Susan M Blaney James M Croop Gregory H Reaman Peter C Adamson 《Journal of clinical oncology》2005,23(25):6172-6180
PURPOSE: Epidermal growth factor receptor is expressed in pediatric malignant solid tumors. We conducted a phase I trial of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in children with refractory solid tumors. PATIENTS AND METHODS: Gefitinib (150, 300, 400, or 500 mg/m2) was administered orally to cohorts of three to six patients once daily continuously until disease progression or significant toxicity. Pharmacokinetic studies were performed during course one (day 1 through 28). RESULTS: Of the 25 enrolled patients, 19 (median age, 15 years) were fully evaluable for toxicity and received 54 courses. Dose-limiting toxicity was rash in two patients treated with 500 mg/m2 and elevated ALT and AST in one patient treated with 400 mg/m2. The maximum-tolerated dose was 400 mg/m2/d. The most frequent non-dose-limiting toxicities were grade 1 or 2 dry skin, anemia, diarrhea, nausea, and vomiting. One patient with Ewing's sarcoma had a partial response. Disease stabilized for 8 to > or = 60 weeks in two patients with Wilms' tumor and two with brainstem glioma (one exophytic). At 400 mg/m2, the median peak gefitinib plasma concentration was 2.2 microg/mL (range, 1.2 to 3.6 microg/mL) and occurred at a median of 2.3 hours (range, 2.0 to 8.3 hours) after drug administration. The median apparent clearance and median half-life were 14.8 L/h/m2 (range, 3.8 to 24.8 L/h/m2) and 11.7 hours (range, 5.6 to 22.8 hours), respectively. Gefitinib systemic exposures were comparable with those associated with antitumor activity in adults. CONCLUSION: Oral gefitinib is well tolerated in children. Development of the drug in combination with cytotoxic chemotherapy will be pursued. 相似文献
73.
74.
75.
Lidong Zhang James E Littlejohn Yu Cui Xiaobo Cao Chander Peddaboina W Roy Smythe 《Molecular cancer》2010,9(1):110
Background
Bortezomib, a proteasome-specific inhibitor, has emerged as a promising cancer therapeutic agent. However, development of resistance to bortezomib may pose a challenge to effective anticancer therapy. Therefore, characterization of cellular mechanisms involved in bortezomib resistance and development of effective strategies to overcome this resistance represent important steps in the advancement of bortezomib-mediated cancer therapy. 相似文献76.
77.
78.
79.
80.
Christopher D Gardner James L Zehnder Alison J Rigby Joel R Nicholus John W Farquhar 《Blood coagulation & fibrinolysis》2007,18(8):787-793
Several case reports have implicated Ginkgo biloba in clinically adverse bleeding disorders. Ginkgo biloba has been reported to increase pain-free walking distance among patients with peripheral artery disease (PAD). Standard PAD therapy includes 325 mg/day aspirin. The objective of this study was to examine potential adverse effects of concomitant aspirin and Ginkgo biloba on platelet function. Ginkgo biloba (EGb 761, 300 mg/day) was compared with placebo for effects on measures of platelet aggregation among adults consuming 325 mg/day aspirin in a randomized, double-blind, placebo-controlled, parallel design trial of 4-week duration. Participants were adults, age 69 +/- 10 years, with PAD or risk factors for cardiovascular disease. Outcome measures included platelet function analysis (PFA-100 analyzer) using ADP as an agonist (n = 26 placebo; n = 29 ginkgo), and platelet aggregation using ADP, epinephrine, collagen and ristocetin as agonists (n = 21 placebo; n = 23 ginkgo). Participants kept daily logs of bleeding or bruising episodes. There were no clinically or statistically significant differences between treatment groups for any agonists, for either PFA-100 analysis or platelet aggregation. Reports of bleeding or bruising were infrequent and similar for both study groups. In conclusion, in older adults with PAD or cardiovascular disease risk, a relatively high dose of Ginkgo biloba combined with 325 mg/day daily aspirin did not have a clinically or statistically detectable impact on indices of coagulation examined over 4 weeks, compared with the effect of aspirin alone. No adverse bleeding events were observed, although the trial was limited to a small sample size. 相似文献